original ) (raw )Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
Ceri Phillips
BMC musculoskeletal disorders, 2006
View PDFchevron_right
Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population
Alberto Rodriguez
Gastroenterology, 2007
View PDFchevron_right
Gastroprotective strategies among NSAID users Guidelines for appropriate use in chronic illness
Laura Targownik
View PDFchevron_right
Address of the authors GASTROINTESTINAL COMPLICATIONS DURING USE OF ANTI-INFLAMMATORY DRUGS
Alessandro Geraci
View PDFchevron_right
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review
Lee Hooper
BMJ, 2004
View PDFchevron_right
Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks
P. Moayyedi
Alimentary Pharmacology & Therapeutics, 2009
View PDFchevron_right
The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs
Colleen Metge
Gastroenterology, 2008
View PDFchevron_right
Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity?
Alexander McMahon
Annals of Internal Medicine, 2000
View PDFchevron_right
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Antiplatelet Agents
Neena Abraham
American Journal of Gastroenterology, 2008
View PDFchevron_right
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
William Sandborn
2002
View PDFchevron_right
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
Angel Lanas
Drug, Healthcare and Patient Safety, 2009
View PDFchevron_right
Management of Gastroduodenopathy Associated With Use of Nonsteroidal Anti-Inflammatory Drugs
David Loeb
Mayo Clinic Proceedings, 1992
View PDFchevron_right
Cardiovascular and gastrointestinal safety of NSAIDs
Eric Tjwa
Pharmaceutisch weekblad, 2014
View PDFchevron_right
NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?
Carmelo Scarpignato
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
Gastroprotection and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Jeremy Hayllar
Drug Safety, 1992
View PDFchevron_right
Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population
Elham Rahme , Sheldon Kong
Arthritis & Rheumatism, 2002
View PDFchevron_right
Individual NSAIDs and Upper Gastrointestinal Complications
Miriam Sturkenboom
Drug Safety, 2012
View PDFchevron_right
Current Perspectives in NSAID-Induced Gastropathy
TEJ SINGH
Mediators of Inflammation, 2013
View PDFchevron_right
Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists
Maryse Lapeyre-mestre
European Journal of Clinical Pharmacology, 2003
View PDFchevron_right
Are the clinical guideline recommendations on gastroprotection being followed? A review in patients taking nonsteroidal anti-inflammatory drugs
Luis Uscanga
Revista de Gastroenterología de México (English Edition), 2016
View PDFchevron_right
Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
Neville Yeomans
BMC Medicine, 2015
View PDFchevron_right
Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals
Joel Kremer
Arthritis & Rheumatism, 2006
View PDFchevron_right
COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
Richard Day
2003
View PDFchevron_right
Risks and benefits of COX2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
hacene nedjar
Rheumatology, 2007
View PDFchevron_right
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage
Benjamin Krevsky
Arthritis Research & Therapy, 2013
View PDFchevron_right
Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs
Walter Smalley
Gastroenterology, 2007
View PDFchevron_right
NSAIDs: a clinical approach to the problems of gastrointestinal side-effects
Michael Hosokawa
Alimentary Pharmacology & Therapeutics, 2007
View PDFchevron_right
A Very High Rate of Inappropriate Use of Gastroprotection for Nonsteroidal Anti-inflammatory Drug Therapy in Primary Care
Riccardo Marmo
Journal of Clinical Gastroenterology, 2011
View PDFchevron_right
National Adherence to Evidence-Based Guidelines for the Prescription of Nonsteroidal Anti-Inflammatory Drugs
Peter Richardson
Gastroenterology, 2005
View PDFchevron_right
Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs
José Eluf-Neto
International journal of clinical practice. Supplement, 2003
View PDFchevron_right
Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project
bod csongor
View PDFchevron_right
NSAIDs: the Emperor's new dogma?
I. Bjarnason
Gut, 2003
View PDFchevron_right